Hillstream BioPharma Announces Proposed Public Offering
April 27, 2023 16:00 ET
|
Hillstream BioPharma, Inc.
BRIDGEWATER, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting...
Hillstream BioPharma Selects OncoBay Clinical to Advance Clinical and Regulatory Development for its Lead Drug Candidate HSB-1216, an Anti-Cancer Mechanism
April 13, 2023 08:47 ET
|
Hillstream BioPharma, Inc.
BRIDGEWATER, N.J., April 13, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting...
Hillstream BioPharma Announces Pharmacokinetic Data of HSB-1216 Supportive of its Development Strategy and Pre-clinical Data
April 10, 2023 08:47 ET
|
Hillstream BioPharma, Inc.
BRIDGEWATER, N.J., April 10, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing a portfolio of therapeutic...
Hillstream BioPharma to Participate in Two Major Industry Conferences in April 2023
March 28, 2023 08:47 ET
|
Hillstream BioPharma, Inc.
BRIDGEWATER, N.J., March 28, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting...
Hillstream BioPharma to Attend the 35th Annual ROTH Conference on March 12-14, 2023
February 28, 2023 09:45 ET
|
Hillstream BioPharma, Inc.
Management will hold 1-on-1 meetings with institutional investors and analystsCompany recently signed an exclusive option agreement with Applied Biomedical Science Institute (ABSI) to license...
Hillstream BioPharma Regains Compliance with Nasdaq Listing Minimum Bid Price Rule
February 15, 2023 07:11 ET
|
Hillstream BioPharma, Inc.
Company Hosted its R&D Day to Discuss Product and Pipeline Goals Across 4 Pipeline Candidates and its Quatramer™ Tumor-Targeting Platform; Multiple inflection points over the next 12-18 Months ...
Hillstream BioPharma Provides Webcast for its R&D Day on February 14th, 2023 at 10:00am ET
February 13, 2023 16:15 ET
|
Hillstream BioPharma, Inc.
Company’s Novel Emerging Anti-Cancer Mechanism, Ferroptosis, Addresses Potential Key Target Oncology Markets Projected to reach $11 Billion in 2028 Signs Exclusive Option Agreement with Applied...
Hillstream BioPharma Signs Exclusive Option Agreement with Applied Biomedical Science Institute (ABSI) to License Technology for HER2 and HER3 to be Developed for Potential Treatments Against Drug Resistant Cancers Including HER2-Positive Metastatic Breast Cancer, Gastric Cancer, Lung Cancer and Ovarian Cancer
February 13, 2023 07:11 ET
|
Hillstream BioPharma, Inc.
HER2 and HER3 Conformational Domain Bridging Epitopes in Antibodies via an Exclusive Option Allows Hillstream BioPharma to Develop Proprietary Multi-format Biologics (bispecific, ADC, CAR-T) against...
In a KRAS G12C-mutated NSCLC cell line, Calu-1, Hillstream BioPharma Demonstrated Significantly Greater Tumor Inhibition Combining Pembrolizumab, an anti-PD-1 antibody, and HSB-1216, a Ferroptosis Inducer
February 10, 2023 07:17 ET
|
Hillstream BioPharma, Inc.
Synergy and crosstalk between Ferroptosis and the Anti-PD-1 Pathways in KRAS G12C-mutated non-small cell lung cancer (NSCLC) cells Lung cancer remains one of the leading causes of cancer-related...
Hillstream BioPharma Announces Acceptance of Abstract at AACR 2023 Annual Meeting Highlighting HSB-510 as Novel Bi-functional Inhibitor for Solid Tumors & Leukemias
February 08, 2023 07:11 ET
|
Hillstream BioPharma, Inc.
Preclinical Update on HSB-510 and navitoclax, a Novel Quatramer™-based, First-in-Class Dual Inhibitor of PI3-Kδ/HDAC6 in combination with navitoclax (BCL-XL/BCL-2 inhibitor) BRIDGEWATER, N.J., Feb. ...